Estrella Immunopharma Inc. (ESLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $22.36M
Last updated: Nov 17, 2026 at 11:05 AM ET
Estrella Immunopharma Inc. (ESLA) Competitors
The companies most similar to Estrella Immunopharma are INmune Bio (INMB), Lite Strategy (LITS) and Marker Therapeutics (MRKR). By market cap, Estrella Immunopharma ranks 11th of the 13 companies on this page; ImageneBio (IMA) is the largest at $43.22M.
Peer Comparison
ESLA's revenue growth of 0.0% is above the peer median of -1.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Estrella Immunopharma (ESLA) | $22.36M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| INmune Bio Inc (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| Lite Strategy, Inc. (LITS) | $25.30M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Instil Bio Inc. (TIL) | $41.23M | N/A | N/A | 0.0% | -11.9% | 0.0% | 0.00% |
| Edesa Biotech Inc (EDSA) | $26.21M | N/A | N/A | 0.0% | N/A | -99.9% | 0.00% |
| Cocrystal Pharma Inc (COCP) | $18.88M | N/A | 39.2x | 0.0% | N/A | 26.9% | 0.00% |
| Barinthus Biotherapeutics plc (BRNS) | $30.23M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| CEL-SCI Corp (CVM) | $22.51M | N/A | N/A | 0.0% | -109.0% | -62.7% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Peer median | $27.97M | N/A | 26.8x | 0.0% | -109.0% | -1.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Estrella Immunopharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| INmune Bio Inc (INMB) | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease... | INMB competitors |
| Lite Strategy, Inc. (LITS) | Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. | LITS competitors |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Instil Bio Inc. (TIL) | Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. | TIL competitors |
| Edesa Biotech Inc (EDSA) | Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, is engaged in the research and development... | EDSA competitors |
| Cocrystal Pharma Inc (COCP) | Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic... | COCP competitors |
| Barinthus Biotherapeutics plc (BRNS) | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system... | BRNS competitors |
| CEL-SCI Corp (CVM) | CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. | CVM competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
Frequently Asked Questions About ESLA
Who are Estrella Immunopharma's main competitors?
The companies most similar to Estrella Immunopharma include INmune Bio (INMB), Lite Strategy (LITS), Marker Therapeutics (MRKR), Plus Therapeutics (PSTV) and Telomir Pharmaceuticals, Inc. Common Stock (TELO), listed from the closest match.
Who is Estrella Immunopharma's biggest competitor?
ImageneBio (IMA) is the largest of the similar companies at $43.22M; INmune Bio (INMB) is the closest match by business profile, size, sector and industry.
How does ESLA stock compare with its competitors?
ESLA's net margin is 0.0% against a peer median of 0.0%.
Which of Estrella Immunopharma's competitors pays a higher dividend?
Estrella Immunopharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Estrella Immunopharma bigger than its competitors?
No. Estrella Immunopharma is 11th by market cap among the 13 companies on this page; the largest is ImageneBio (IMA) at $43.22M.
ESLA pages: Overview, Earnings, Forecast, Financials, Competitors